Examine Bio-Rad's (BIO) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.

BIO misses Q4 EPS estimates as margins shrank and shares slid 12%, despite revenue growth and a rebound in Clinical Diagnostics sales.

Bio-Rad Laboratories, Inc. (NYSE: BIO - Get Free Report) has earned a consensus recommendation of "Hold" from the six research firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have given a buy recommendation to the company. The

Bio-Rad Laboratories, Inc. (BIO) Q4 2025 Earnings Call Transcript

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.51 per share, missing the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.9 per share a year ago.

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. Norman Schwartz, Bio-Rad's Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and.

Allianz Asset Management GmbH raised its holdings in Bio-Rad Laboratories, Inc. (NYSE: BIO) by 22.7% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 66,549 shares of the medical research company's stock after purchasing an additional 12,310 shares during the period.

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the fourth quarter and full year 2025 on Thursday, February 12, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-196.

BIO-key EMEA Partners with Citadel Global to Expand India Presence & Accelerate Adoption of Identity Solutions in Support of EU–India trade agreement

BKYI: BIO-key & Visualforma awarded contract to Secure digital identities for large municipality in Portugal, enabling modern efficient citizen serivces.